ValiRx PLC Publication of VAL401 peer-reviewed article
January 11 2019 - 1:00AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
11 January 2019
VALIRX PLC
("ValiRx" or the "Company")
UPDATE ON VAL401
"Publication of article in the 'European Journal of Drug
Metabolism and Pharmacokinetics"
"First published peer-reviewed journal article on VAL401
clinical trial results"
London, UK., 11 January 2019: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, is pleased to announce that
further to its announcement on 18 December 2018, the Company notes
that its peer-reviewed article, entitled: "Clinical
Pharmacokinetics of a Lipid-Based Formulation of Risperidone,
VAL401: Analysis of a Single Dose in an Open-Label Trial of
Late-Stage Cancer Patients", has now been published online in the
European Journal of Drug Metabolism and Pharmacokinetics and can be
viewed via the following link: Dilly, S.J., Morris, G.S., Taylor,
P.C. et al. Eur J Drug Metab Pharmacokinet (2019).
https://doi.org/10.1007/s13318-018-00538-4
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Novum Securities Limited Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from World class institutions,
such as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRASFFFMSFUSESF
(END) Dow Jones Newswires
January 11, 2019 02:00 ET (07:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024